Leo Pharma AS
Latest From Leo Pharma AS
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.
India's Sun has licensed out treatments for psoriasis and dry eye to a new partner for selected Asian markets and China, which it expects to emerge as a key market for its products.
Up to two thirds of patients with psoriatic arthritis experience inflammatory back pain and the Swiss major has presented data showing that its best-selling drug achieved rapid and significant improvements.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- Respiratory, Pulmonary
- Leo Pharmaceutical Products Ltd.
- Western Europe
- Parent & Subsidiaries
- Leo Pharma AS
- Senior Management
Catherine Mazzacco, Pres. & CEO
Anders Kronborg, EVP, Global Fin. & Bus. Services
Kim Kjoller, EVP, Global R&D
- Contact Info
Leo Pharma AS
Phone: (45) 4494 5888
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.